Symbol
| CREBBP
| contributors: mct/npt/pgu - updated : 21-02-2018
|
HGNC name
| CREB binding protein
|
HGNC id
| 2348
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
| fusion
|  
|  
|  
|
with MYST3 in acute myeloid leukemia with translocation t(8;16)(p11;p13), see AML3, and with MLL (HRX) in therapy related acute leukemia with translocation t(11;16)(q23;p13), with MYST4 in AML with t(10;16) (q22;p13) | tumoral
| fusion
|  
|  
|  
|
fusion genes MYST3-CREBBP in acute myeloid leukemia (AML) by chromosomal translocation | tumoral
| somatic mutation
|  
|  
| loss of function
|
in B-cell non-Hodgkin lymphoma | tumoral
| somatic mutation
|  
|  
|  
|
in relapsed acute lymphoblastic leukaemia, mutations impaired histone acetylation and transcriptional regulation of CREBBP targets, including glucocorticoid responsive genes, and may confer resistance to therapy ( | tumoral
| somatic mutation
|  
|  
|  
|
in hypothalamic hamartoma with gelastic epilepsy | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
cancer | hemopathy | | |
use of histone deacetylase inhibitors has a potential therapy in B-cell non-Hodgkin lymphoma | cancer | hemopathy | | |
promising therapeutic targets across multiple subtypes in acute myeloid leukemia |
| | | |
| mice with a deletion mutation in the CBP CH1 (TAZ1) domain have an Rubinstein-Taybi Syndrome (RTS)-like phenotype that includes ASD-relevant repetitive behaviors, hyperactivity, social interaction deficits, motor dysfunction, impaired recognition memory, and abnormal synaptic plasticity |